特朗普政府推动生物相似物降低生物药物成本,但迄今节省的资金有限。 The Trump administration pushes biosimilars to cut biologic drug costs, with limited savings so far.

用于治疗癌症和自生免疫疾病等严重病症的生物药物仅占处方的5%,但由于制造复杂和林业发展局审批程序长达10至15年,在美国药物支出中占一半以上。 Biologic drugs, used to treat serious conditions like cancer and autoimmune diseases, make up just 5% of prescriptions but over half of U.S. drug spending due to complex manufacturing and lengthy 10- to 15-year FDA approval processes. 特朗普政府正在推广生物相似——非常相似但并不相同的生物logics版本——作为降低成本、加快批准速度和确保与毒品制造者进行定价交易的一种方式。 The Trump administration is promoting biosimilars—highly similar but not identical versions of biologics—as a way to lower costs, accelerating their approval and securing pricing deals with drugmakers. 虽然生物类同的核准需要5至6年,而且保险和谈判利率的节省也各不相同,但有些人提供15%至35%的折扣,现金价格低至每月550美元。 Though biosimilar approval takes five to six years and savings vary by insurance and negotiated rates, some offer discounts of 15% to 35%, with cash prices as low as $550 per month. 尽管作出了这些努力,但普遍降低成本仍然不确定。 Despite these efforts, widespread cost reductions remain uncertain.